HomeNewsBusinessWhat does US major Accenture's strong growth outlook say about Indian IT industry?

What does US major Accenture's strong growth outlook say about Indian IT industry?

The strong deal wins and outlook for FY21 indicate the healthy demand for coming quarters by the Indian IT services firms as customers continue to invest in digital.

December 18, 2020 / 14:35 IST
Story continues below Advertisement

US-based IT services firm Accenture's first-quarter showing may have some good tidings for the likes of TCS, Infosys and Wipro.

Accenture reported a 3.5 percent year-on-year revenue growth at $11.8 billion for its first quarter ending November 30, 2020. The company expects full revenue growth of 4-6 percent in FY21.

Story continues below Advertisement

New deal booking too increased by 25 percent year-on-year at $12.9 billion from $10.3 billion in Q1 FY20.

During the quarter, the company added 8,555 people taking the total headcount to 5,14,288 globally. Amid COVID-19, the company had laid off close to 5 percent of its employees, including in India. The IT major employs about 2 lakh people in the country.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show